TrialJournal of neurology2024

Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measures.

Stewart J Tepper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.